On the origins of enzyme inhibitor selectivity and promiscuity
This entry was posted in Uncategorized and tagged Active site, Drug Design, Drug Discovery, Enzyme Inhibitor, kinase, Kinase inhibitor, Ligand, selectivity, Shape Analysis. Bookmark the permalink.